LentiGlobin for Sickle Cell Disease Gene Therapy Overview
DP, drug product; HSCs, hematopoietic stem cells; RBCs, red blood cells
Two Current Studies
- HGB-206: A study evaluating the safety and efficacy of the LentiGlobin BB305 drug product in severe Sickle Cell Disease (open but closed to recruitment.)
- HGB210: Phase 3 HGB-210 study of LentiGlobin in patients with Sickle Cell Disease (coming soon.)